search
Back to results

Intestinal Permeability in Obesity (LEAKY GUT)

Primary Purpose

Obesity, Metabolic Diseases, Nutrition Disorders

Status
Terminated
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Intestinal permeability
a solution of mannitol and lactitol
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Obesity focused on measuring Obesity, Intestinal permeability, Adipose tissue inflammation, Low grade systemic inflammation, Bariatric surgery

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

- Control subjects T1:

  1. Registered for social security
  2. Signed consent form
  3. male or female subject between 18 and 65 years old
  4. Fasting plasma triglycerides < 1.5 g/l (< 1.7 mmol/l)
  5. Fasting plasma total cholesterol < 2.5 g/l (< 6 mmol/l)
  6. fasting glycaemia < 5,5 mmol/l
  7. BMI <25kg/m² & >18 kg/m²
  8. Mean systolic blood pressure <140 mmHg and mean diastolic blood pressure < 90 mmHg.

Control subjects T2

  1. Registered for social security
  2. Signed consent form
  3. male or female subject between 18 and 70 years old
  4. IMC<25kg/m² et >18 kg/m²
  5. candidate to surgery giving access to jejunal samples

Obese subjects OB:

  1. Registered for social security
  2. Signed consent form
  3. male or female subject between 18 and 65 years old
  4. Candidate to bariatric surgery (bypass) with massive (IBMI >= 40 kg/m²) or severe obesity (BMI between 35 & 40 kg/m²) with at least one obesity-related comorbidity and with a stable weight (+/-5kg) for the last 3 months, after approval by a multidisciplinary team

Exclusion criteria :

- Control subjects T1:

  1. Subject with a history of vascular symptomatic disease in the last 6 months before selection.
  2. Subject receiving a treatment that can affect measured parameters
  3. Pregnancy
  4. Subject with acute or chronic disease that can affect measured parameters or to life-threatening. Including but not limited :

    1. Diabetic subjects
    2. Subject with kidney disease: nephrotic syndrome, chronic renal failure
    3. Subject having a gastrointestinal disorder or disease limiting intestinal absorption (celiac disease), bariatric surgery.
    4. Active inflammatory disease or a history of IBD
  5. Subject in a situation that, according to the investigator's opinion could interfere with an optimal participation to the study or constitute a particular risk to the subject
  6. Subject in an exclusion period after participating in another clinical trial
  7. Adult person subject to legal protection or unable to consent.
  8. Persons deprived of their liberty by judicial or administrative decision

Control subjects T2

  1. Subject with a history of symptomatic vascular disease (myocardial infarction, angina syndrome threat, surgical or endovascular surgery, stroke, lower limb arteritis symptomatic) of less than 6 months
  2. Subject with any acute or chronic disease which may influence the results of the study or to life-threatening. Including but not limiting:

    1. diabetic patients
    2. Subject with kidney disease: nephrotic syndrome, chronic renal failure and / or serum creatinine> 1.7 times the upper limit of the reference value
  3. Adult person subject to legal protection or unable to consent.
  4. Persons deprived of their liberty by judicial or administrative decision

Obese subjects candidates for surgery:

  1. Subject receiving treatment systemically or topically, which may interfere with the evaluation of the parameters studied (NSAIDs, antibiotics in the previous month)
  2. Any disease or psychosocial context making prolonged regular monitoring impossible, which also represents a contraindication for bariatric surgery.
  3. Adult person subject to legal protection or unable to consent.
  4. Persons deprived of their liberty by judicial or administrative decision

Sites / Locations

  • Groupe Hospitalier Pitié-Salpêtrière

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

No Intervention

Arm Label

obese group

non-obese control group (T1)

non obese control group undergoing a surgery (T2)

Arm Description

40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months

30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS

40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins

Outcomes

Primary Outcome Measures

urinary lactitol / mannitol ratio by an intestinal permeability test (IPT)
Measures of urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) in obese patients before gastric bypass and 6 months after

Secondary Outcome Measures

fasting zonulin serum concentrations
Measures of fasting zonulin serum concentrations in obese patients before gastric bypass and 6 months after
LPS serum concentrations
Measures of LPS serum concentrations in obese patients before gastric bypass and 6 months after
urinary lactitol / mannitol ratio by an intestinal permeability test (IPT)
Measures of urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) in non-obese control subjects, performed twice with a one-month interval.
surgical samples during surgery (sub-cutaneous and visceral adipose tissue)

Full Information

First Posted
November 12, 2014
Last Updated
January 15, 2021
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institute of Cardiometabolism and Nutrition, France
search

1. Study Identification

Unique Protocol Identification Number
NCT02292121
Brief Title
Intestinal Permeability in Obesity
Acronym
LEAKY GUT
Official Title
Intestinal Permeability in Obesity of Intercellular Tight Junctions to Metabolic Complications
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Terminated
Why Stopped
lack of surgical controls
Study Start Date
February 24, 2014 (Actual)
Primary Completion Date
March 17, 2016 (Actual)
Study Completion Date
March 17, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Institute of Cardiometabolism and Nutrition, France

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In rodents, obesity is associated with changes in tight junctions' structure in small intestine, which impacts intestinal permeability and results in metabolic complications. Few data exist in human. We hypothesized that intestinal permeability is altered in obese subjects in comparison to lean subjects, linked to metabolic and inflammatory status and that these alterations are modified after gastric bypass.
Detailed Description
The regulation of the permeability of the intestinal barrier is essential in the molecular traffic between the lumen and the internal environment. It affects the absorption of nutrients and tolerance or immunization against foodborne non-self antigens that penetrate the barrier. In rodents, increased endotoxemia has been proposed as an important player in low-grade inflammation accompanying the development of obesity and metabolic disorders. In humans, the intestinal barrier function is altered in inflammatory bowel diseases (IBD, Crohn's disease, ulcerative colitis and celiac disease). The term "leaky gut" is used to describe a porous intestine with hyper-permeability associated with acute or chronic inflammatory diseases such as "systemic inflammatory response syndrome (SIRS),"acute inflammatory bowel disease (IBD for "inflammatory bowel disease"). Deficiencies of the barrier are also observed in extra-intestinal diseases (type-1 diabetes, food allergies, and autoimmune diseases). Impairments in tight junctions may precede clinical signs and constitute a risk factor for developing diseases or secondarily be altered and cause an increased entry of undesirable bacterial or nutritional antigens. The state of the intercellular tight junctions of the intestine controls the diffusion of molecules between cells. A deficiency of the intestinal barrier function is often associated with structural changes in the tight junctions resulting from loss of localization of protein or expression of genes and / or cellular signals such as ZO-1, occludin or tricellulin. There are few studies about the condition of the intestinal barrier in the context of human obesity. The objectives of our study are to : compare intestinal permeability in obese subjects with non obese subjects and after gastric bypass. search links between intestinal permeability and 1) metabolic and inflammatory bioclinical parameters 2) dietary profiles 3) microbiota

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Metabolic Diseases, Nutrition Disorders, Body Weight
Keywords
Obesity, Intestinal permeability, Adipose tissue inflammation, Low grade systemic inflammation, Bariatric surgery

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
obese group
Arm Type
Experimental
Arm Description
40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
Arm Title
non-obese control group (T1)
Arm Type
Active Comparator
Arm Description
30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
Arm Title
non obese control group undergoing a surgery (T2)
Arm Type
No Intervention
Arm Description
40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins
Intervention Type
Procedure
Intervention Name(s)
Intestinal permeability
Intervention Description
5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
Intervention Type
Other
Intervention Name(s)
a solution of mannitol and lactitol
Primary Outcome Measure Information:
Title
urinary lactitol / mannitol ratio by an intestinal permeability test (IPT)
Description
Measures of urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) in obese patients before gastric bypass and 6 months after
Time Frame
before gastric bypass and 6 months after
Secondary Outcome Measure Information:
Title
fasting zonulin serum concentrations
Description
Measures of fasting zonulin serum concentrations in obese patients before gastric bypass and 6 months after
Time Frame
before gastric bypass and 6 months after
Title
LPS serum concentrations
Description
Measures of LPS serum concentrations in obese patients before gastric bypass and 6 months after
Time Frame
before gastric bypass and 6 months after
Title
urinary lactitol / mannitol ratio by an intestinal permeability test (IPT)
Description
Measures of urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) in non-obese control subjects, performed twice with a one-month interval.
Time Frame
inclusion and after one month
Title
surgical samples during surgery (sub-cutaneous and visceral adipose tissue)
Time Frame
intraoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria : - Control subjects T1: Registered for social security Signed consent form male or female subject between 18 and 65 years old Fasting plasma triglycerides < 1.5 g/l (< 1.7 mmol/l) Fasting plasma total cholesterol < 2.5 g/l (< 6 mmol/l) fasting glycaemia < 5,5 mmol/l BMI <25kg/m² & >18 kg/m² Mean systolic blood pressure <140 mmHg and mean diastolic blood pressure < 90 mmHg. Control subjects T2 Registered for social security Signed consent form male or female subject between 18 and 70 years old IMC<25kg/m² et >18 kg/m² candidate to surgery giving access to jejunal samples Obese subjects OB: Registered for social security Signed consent form male or female subject between 18 and 65 years old Candidate to bariatric surgery (bypass) with massive (IBMI >= 40 kg/m²) or severe obesity (BMI between 35 & 40 kg/m²) with at least one obesity-related comorbidity and with a stable weight (+/-5kg) for the last 3 months, after approval by a multidisciplinary team Exclusion criteria : - Control subjects T1: Subject with a history of vascular symptomatic disease in the last 6 months before selection. Subject receiving a treatment that can affect measured parameters Pregnancy Subject with acute or chronic disease that can affect measured parameters or to life-threatening. Including but not limited : Diabetic subjects Subject with kidney disease: nephrotic syndrome, chronic renal failure Subject having a gastrointestinal disorder or disease limiting intestinal absorption (celiac disease), bariatric surgery. Active inflammatory disease or a history of IBD Subject in a situation that, according to the investigator's opinion could interfere with an optimal participation to the study or constitute a particular risk to the subject Subject in an exclusion period after participating in another clinical trial Adult person subject to legal protection or unable to consent. Persons deprived of their liberty by judicial or administrative decision Control subjects T2 Subject with a history of symptomatic vascular disease (myocardial infarction, angina syndrome threat, surgical or endovascular surgery, stroke, lower limb arteritis symptomatic) of less than 6 months Subject with any acute or chronic disease which may influence the results of the study or to life-threatening. Including but not limiting: diabetic patients Subject with kidney disease: nephrotic syndrome, chronic renal failure and / or serum creatinine> 1.7 times the upper limit of the reference value Adult person subject to legal protection or unable to consent. Persons deprived of their liberty by judicial or administrative decision Obese subjects candidates for surgery: Subject receiving treatment systemically or topically, which may interfere with the evaluation of the parameters studied (NSAIDs, antibiotics in the previous month) Any disease or psychosocial context making prolonged regular monitoring impossible, which also represents a contraindication for bariatric surgery. Adult person subject to legal protection or unable to consent. Persons deprived of their liberty by judicial or administrative decision
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christine POITOU, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Groupe Hospitalier Pitié-Salpêtrière
City
Paris
ZIP/Postal Code
75013
Country
France

12. IPD Sharing Statement

Learn more about this trial

Intestinal Permeability in Obesity

We'll reach out to this number within 24 hrs